Rein Therapeutics, Inc. 8K

Rein Therapeutics furnished an investor presentation describing the clinical development status and supporting data for its lead IPF drug candidate LTI-03 and related fibrosis programs, including an ongoing Phase 2 trial.

Rein Therapeutics, Inc. furnished an investor presentation (Exhibit 99.1) outlining its clinical‑stage fibrosis pipeline, with a primary focus on LTI-03, a novel inhaled caveolin-1 scaffolding domain peptide being advanced as a potential first‑in‑class treatment for idiopathic pulmonary fibrosis (IPF); the deck summarizes preclinical antifibrotic and regenerative data, completed Phase 1b safety and biomarker results, and the ongoing enrollment of the RENEW Phase 2 IPF trial (NCT06968845), as well as providing forward‑looking statements regarding expected clinical milestones and the company’s cash runway into early 2028.

Filing Facts

CIK

1420565

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-383726

Alert Tier

5